BioAdaptives® Announces Commercial Launch of MyndMed™ Following Successful Pilot Testing
BioAdaptives (OTC: BDPT) announced the commercial launch of MyndMed™, a cognitive-support dietary supplement available online as of October 7, 2025.
The company said MyndMed™ combines well-studied nutrients targeting cholinergic tone, neuronal energy metabolism, antioxidant defenses, and neuroplasticity, and that manufacturing occurs in cGMP-certified U.S. facilities with third‑party testing and transparent labeling. BioAdaptives is scaling production to meet expected high order volumes beginning in November and offers nationwide U.S. shipping, introductory promotions, and subscription options at www.MyndMed.com.
BioAdaptives (OTC: BDPT) ha annunciato il lancio commerciale di MyndMed™, un integratore alimentare di supporto cognition disponibile online a partire dal 7 ottobre 2025.
L'azienda afferma che MyndMed™ combina nutrienti ampiamente studiati mirati al tono colinergico, al metabolismo energetico neuronale, alle difese antiossidanti e alla neuroplasticità, e che la produzione avviene in impianti statunitensi cGMP-certificati con test di terze parti e etichettatura trasparente. BioAdaptives sta ampliando la produzione per soddisfare i volumi di ordini previsti a partire da novembre e offre spedizioni a livello nazionale negli Stati Uniti, promozioni introduttive e opzioni di abbonamento su www.MyndMed.com.
BioAdaptives (OTC: BDPT) anunció el lanzamiento comercial de MyndMed™, un suplemento dietético de apoyo cognitivo disponible en línea a partir del 7 de octubre de 2025.
La compañía dijo que MyndMed™ combina nutrientes bien estudiados que apuntan al tono colinérgico, al metabolismo energético neuronal, a las defensas antioxidantes y a la neuroplasticidad, y que la fabricación se realiza en instalaciones en EE. UU. certificadas por cGMP con pruebas de terceros y etiquetado transparente. BioAdaptives está escalando la producción para satisfacer los volúmenes de pedidos esperados a partir de noviembre y ofrece envíos en todo el país, promociones de introducción y opciones de suscripción en www.MyndMed.com.
BioAdaptives (OTC: BDPT)는 MyndMed™의 상용 출시를 발표했습니다. 이는 2025년 10월 7일부터 온라인으로 이용 가능한 인지 지원 보충제입니다.
회사는 MyndMed™가 콜린성 톤, 신경 에너지 대사, 항산화 방어 및 신경가소성을 목표로 잘 연구된 영양소를 결합한다고 말하며, 제조는 미국 cGMP 인증 시설에서 이루어지며 제3자 테스트와 투명한 라벨링이 이루어진다고 밝혔습니다. BioAdaptives는 11월부터 예상되는 높은 주문량에 대응하기 위해 생산을 확대 중이며, 미국 전역 배송, 도입 프로모션 및 구독 옵션을 www.MyndMed.com에서 제공합니다.
BioAdaptives (OTC: BDPT) a annoncé le lancement commercial de MyndMed™, un complément alimentaire de soutien cognitif disponible en ligne à partir du 7 octobre 2025.
La société a déclaré que MyndMed™ associe des nutriments bien étudiés ciblant le ton cholinergique, le métabolisme énergétique neuronal, les défenses antioxydantes et la neuroplasticité, et que la fabrication se fait dans des installations américaines certifiées cGMP avec des tests par des tiers et un étiquetage transparent. BioAdaptives augmente sa production pour répondre aux volumes de commandes élevés prévus à partir de novembre et propose une expédition à l'échelle nationale aux États-Unis, des promotions d'introduction et des options d'abonnement sur www.MyndMed.com.
BioAdaptives (OTC: BDPT) kündigte den kommerziellen Start von MyndMed™ an, einem kognitiv unterstützenden Nahrungsergänzungsmittel, das ab dem 7. Oktober 2025 online erhältlich ist.
Das Unternehmen sagte, MyndMed™ vereine gut erforschte Nährstoffe, die auf den cholinergen Ton, den neuronalen Energiestoffwechsel, antioxidanze Abwehrkräfte und Neuroplastizität abzielen, und dass die Herstellung in cGMP-zertifizierten US-Einrichtungen erfolgt, mit Drittanbieter-Tests und transparenter Kennzeichnung. BioAdaptives skaliert die Produktion, um ab November voraussichtlich hohe Bestellmengen zu bedienen, und bietet landesweiten Versand in den USA, Einführungskampagnen und Abonnementoptionen unter www.MyndMed.com.
BioAdaptives (OTC: BDPT) أعلنت عن الإطلاق التجاري لـ MyndMed™، وهو مكمل غذائي لدعم الإدراك متاح عبر الإنترنت اعتبارًا من 7 أكتوبر 2025.
قالت الشركة إن MyndMed™ يجمع مغذيات مُدرَة جيدًا تستهدف النغمة الكولينERG، الأيض العصبي للطاقة، الدفاعات المضادة للأكسدة والتحفيز العصبي، والتلدّن العصبي. وأضافت أن التصنيع يتم في مرافق أمريكية معتمدة بموجب cGMP مع اختبارات من طرف ثالث وتسمية شفافة. تقوم BioAdaptives بتوسيع الإنتاج لتلبية أحجام الطلب المرتقبة ابتداءً من نوفمبر وتوفر الشحن على مستوى الولايات المتحدة، وعروض ترويجية تعريفية وخيارات اشتراك على www.MyndMed.com.
BioAdaptives (OTC: BDPT) 宣布商业推出 MyndMed™，这是一种认知支持的膳食补充剂，将于 2025 年 10 月 7 日起在线购买。
公司表示 MyndMed™ 结合了针对胆碱能调性、神经元能量代谢、抗氧化防御和神经可塑性等方面的研究充足的营养素，且在 符合 cGMP 的美国设施 生产，第三方检测和透明标签。BioAdaptives 正在扩大生产以满足 11 月起预计的高订单量，并提供在全美范围内的运输、入门促销以及在 www.MyndMed.com 的订阅选项。
- None.
- None.
Comprehensive cognitive-support formula now available online; company scaling production for anticipated Q4 demand
LAS VEGAS, Oct. 07, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT) today announced the commercial availability of MyndMed™, a next-generation cognitive-support dietary supplement formulated to support memory, focus, mental clarity, and overall brain performance. Following rigorous testing with overwhelmingly positive results, the company is expanding distribution and scaling inventory to meet the expected high order volumes from November onward.
"After extensive testing, we're thrilled to bring MyndMed™ to a wider audience," said James Keener, CEO of BioAdaptives Inc. "Users have reported enhanced focus, reduced brain fog, and sustained energy without the jitters of traditional stimulants. With our soft launch proving demand, we're gearing up for explosive growth this fall, making MyndMed™ accessible to anyone seeking a mental edge in work, sports, or daily life."
Why MyndMed™
MyndMed™ brings together well-studied nutrients to support key cognitive pathways, including cholinergic tone, neuronal energy metabolism, antioxidant defenses, and neuroplasticity. Together, these ingredients are intended to support:
- Short-term: sustained alertness, calm focus, and memory support.
- Mid-term: synaptic efficiency and cognitive processing speed support.
- Long-term: cellular energy, antioxidant balance, and neuroprotective support.
“Our guiding principle with MyndMed™ was to create a first-in-class nootropic that delivers “Mental Armor for Modern Minds™” added James Keener, CEO. “The stack addresses complementary mechanisms—from acetylcholine dynamics to mitochondrial function and antioxidant status—while remaining compliant with World Anti-Doping Association (WADA) regulations.”
Quality & Compliance
- Manufactured in the USA in cGMP-certified facilities.
- Third-party tested for identity, purity, and heavy metals.
- Transparent labeling with no proprietary blends.
Availability & Ordering
MyndMed™ is available now at www.MyndMed.com. The product ships nationwide in the U.S. with standard and expedited options. For introductory promotions and subscription savings, visit the product page.
About BioAdaptives, Inc.
BioAdaptives, Inc. develops and markets science-based natural health and wellness products for both humans and animals. Its formulations leverage cutting-edge research in stem cell biology, adaptogens, and regenerative nutrition. The company’s mission is to enhance the quality of life through innovation that works in harmony with the body’s natural processes.
For more information, visit: www.bioadaptives.com.
Contact:
Emily Harrison
Investor Relations
BioAdaptives, Inc.
(702) 659-8829
info@bioadaptives.com
FAQ
When did BioAdaptives (BDPT) launch MyndMed™ commercially?
Where can investors and customers buy MyndMed™ from BDPT?
How is MyndMed™ manufactured and tested for quality?
What cognitive benefits does BDPT claim MyndMed™ supports?
Is MyndMed™ compliant with sports anti-doping rules mentioned by BDPT?
